UNSPSC 51142307: Levallorphan

This classification denotes an opiate antagonist with the molecular formula C19H25NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 353613BU4U, chemically known as morphinan-3-ol, 17-(2-propenyl)- but generally known as levallorphan, which bears US NIH Compound Identifier 3912. European Medicines Agency schedules Levallorphan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08452MIG. The term LEVALLORPHAN is an International Non-Proprietary Name.

UNSPSC 51142307 Levallorphan is a Commodity code that in practice encompasses opioid-antagonist medications and related pharmaceutical products procured by state and local health authorities. Recent state and local solicitations under this code show demand for naloxone (an opioid-reversal agent), safe drug deactivation systems, and broader generic pharmaceutical and over-the-counter product supply arrangements. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances coordinating procurement across member jurisdictions. The work involves fixed-price or competitive-bid supply contracts with quarterly or ongoing delivery schedules, vendor compliance with federal manufacturing and supply-chain security standards, and insurance and workplace-certification requirements typical of pharmaceutical distribution.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with a response deadline of July 26, 2023, requiring quarterly deliveries to the county community health building and E-Verify compliance. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, an exploratory phase intended to inform future formal solicitation strategy. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026, requiring cGMP and Drug Supply Chain Security Act compliance, authorized-wholesaler distribution through three specified vendors, and 75 percent evaluation weight on price competitiveness.